Department of Cancer Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, China.
Chin Med J (Engl). 2023 Dec 5;136(23):2776-2786. doi: 10.1097/CM9.0000000000002548.
Epidermal growth factor receptor ( EGFR ) mutations are common oncogenic driver mutations in patients with non-small cell lung cancer (NSCLC). The application of EGFR-tyrosine kinase inhibitors (TKIs) is beneficial for patients with advanced and early-stage NSCLC. With the development of next-generation sequencing technology, numerous patients have been found to have more than one genetic mutation in addition to a single EGFR mutation; however, the efficacy of conventional EGFR-TKIs and the optimal treatments for such patients remain largely unknown. Thus, we review the incidence, prognosis, and current treatment regimens of EGFR compound mutations and EGFR concomitant mutations to provide treatment recommendations and guidance for patients with these mutations.
表皮生长因子受体 ( EGFR ) 突变是非小细胞肺癌 (NSCLC) 患者常见的致癌驱动突变。 EGFR-酪氨酸激酶抑制剂 (TKIs) 的应用有利于晚期和早期 NSCLC 患者。随着下一代测序技术的发展，除了单个 EGFR 突变外，许多患者还发现存在不止一种基因突变；然而，传统的 EGFR-TKIs 的疗效和此类患者的最佳治疗方法在很大程度上仍然未知。因此，我们综述了 EGFR 复合突变和 EGFR 伴随突变的发生率、预后和当前的治疗方案，为携带这些突变的患者提供治疗建议和指导。
